US, EU and Australia reveal positive outcomes from pilot GCP and API inspection projects
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration and its counterparts in Europe and Australia have revealed positive findings from two pilot programmes aimed at collaborating on inspections of clinical trials and active pharmaceutical ingredient manufacturing facilities1.
You may also be interested in...
Report: Global API GMP Inspection Coordination Increasing Under Joint Program
Regulators report that an international collaboration on GMP inspections of API sites has bolstered the exchange of information between participating health authorities, yet the information technology system that supports the system could use some improvement.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.